{"id":"NCT02581345","sponsor":"Momenta Pharmaceuticals, Inc.","briefTitle":"Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis","officialTitle":"A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09","primaryCompletion":"2017-04-04","completion":"2017-04-04","firstPosted":"2015-10-21","resultsPosted":"2018-09-12","lastUpdate":"2018-10-17"},"enrollment":572,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Plaque Psoriasis","Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"M923","otherNames":["Adalimumab"]},{"type":"BIOLOGICAL","name":"Humira","otherNames":["Adalimumab"]}],"arms":[{"label":"M923","type":"EXPERIMENTAL"},{"label":"Humira","type":"ACTIVE_COMPARATOR"},{"label":"M923 and Humira","type":"OTHER"}],"summary":"The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16","timeFrame":"Baseline; Week 16","effectByArm":[{"arm":"Part 1: M923","deltaMin":80.1,"sd":null},{"arm":"Part 1: EU RPP","deltaMin":79,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":90,"countries":["United States","Bulgaria","Canada","Czechia","Estonia","Germany","Latvia","Poland","Slovakia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":285},"commonTop":["Injection site reaction","Nasopharyngitis","Psoriasis","Upper respiratory tract infection","Headache"]}}